Mesoblast (NASDAQ:MESO) Upgraded at Cantor Fitzgerald

Mesoblast (NASDAQ:MESO) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a report issued on Monday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Mesoblast’s FY2025 earnings at ($0.71) EPS.

Other equities analysts also recently issued reports about the stock. Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Piper Sandler restated an “overweight” rating and set a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Mesoblast Stock Performance

Shares of NASDAQ MESO opened at $11.82 on Monday. Mesoblast has a 1 year low of $4.60 and a 1 year high of $22.00. The firm has a 50-day simple moving average of $15.97 and a two-hundred day simple moving average of $13.28. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd purchased a new stake in shares of Mesoblast during the fourth quarter worth about $30,000. Barclays PLC acquired a new position in Mesoblast during the 4th quarter valued at approximately $38,000. Lindbrook Capital LLC raised its holdings in shares of Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock worth $43,000 after buying an additional 901 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Mesoblast during the fourth quarter worth $50,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Mesoblast by 86,566.7% during the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock valued at $51,000 after buying an additional 2,597 shares during the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.